There's no stopping you, is there?



Fortunately, newer HIV medications are less likely to produce drug resistance mutations than older HIV medications.

“Today’s HIV treatments work, really well. Once common, HIV drug resistance has become a quite uncommon thing for patients taking modern medications, even among those with less than perfect adherence,” Benjamin Young, MD, PhD, senior vice president and chief medical officer of the International Association of Providers in AIDS Care (IAPAC), told BETA.

In addition, some of the newer drugs today are particularly resistant to resistance.

“Drug resistance is particularly uncommon among people taking first-line HIV integrase inhibitors. This appears to be especially true for dolutegravir (Tivicay), where only a single case of treatment-emergent resistance has been reported during initial treatment. With today’s treatment options, dealing with drug resistant virus is easier, with potent and well-tolerated second-line options,” said Young.
https://www.sfaf.org/collections/bet...ug-resistance/


Also:

New York Says End of AIDS Epidemic Is Near

In New York, where the first cases of AIDS were reported in 1981, fewer than 2,500 new cases were reported in 2018, the lowest in many years.

...Experts in the field say that the progress being made in New York — particularly in New York City, long an epicenter of infection — is the result of a number of factors, including the use of PrEP and the ease of antiretroviral drugs, which suppress levels of H.I.V.

“Those two things together have been a revolution,” said Jen Kates, director of global health and H.I.V. policy at the Kaiser Family Foundation in Washington.
New HIV diagnoses and infections continue to fall to record lows in New York City

It's a 64% drop since the city began reporting new HIV diagnoses in 2001, when more than 5,900 people were diagnosed.
Rapidly declining HIV infection in MSM in central London

So in summary:

People, especially men who have sex with men, have not become careless about HIV. And virus mutation and drug resistance have not turned out to be major problems because combination therapy by designs reduces the risk of it happening.